Introduction
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach to effectively treat cancer while reducing drug-related toxicities by combining the specificity of an antibody with the potency of cytotoxic agents (Reviewed in 1-3). An ADC consists of an antibody that is conjugated with a potent warhead, typically a cytotoxic small molecule, which has been chemically modified with a linker used to conjugate the drug to the antibody. The ADC binds to an antigen on the surface of a cancer cell and the ADC/antigen complex is internalized and trafficked to the lysosome where the cytotoxic agent is released through cleavage of a linker or through proteolytic degradation of the antibody itself if a non-cleavable linker is used to conjugate the warhead to the antibody.
The warhead exits the lysosome where it can then bind to its target; typically either microtubules or DNA, depending on its mechanism of action. The binding of these cytotoxic agents to their targets results in cell cycle arrest that subsequently leads to cell death. Given the generally high potency of cytotoxics most commonly used in ADCs, it is important to identify targets exhibiting both good expression in tumors and limited normal tissue expression in order to reduce the possibility of on-target toxicity.
The oncofetal antigen 5T4, also known as trophoblast glycoprotein (TPBG), is a 72 kDa glycoprotein that is typically only expressed during embryonic development, whereas expression in normal adult tissues is very limited (4, 5) . Expression of 5T4, however, is reported to be significantly upregulated in many types of carcinomas including, but not limited to cancers of the lung, breast, stomach, prostate, colon, and ovaries, and its expression has been correlated with poor prognosis in multiple indications (6) (7) (8) (9) (10) (11) (12) (13) . 4 The biology of 5T4 in normal and pathologic tissues is not well understood. The extracellular domain of 5T4 contains several leucine-rich repeats that have been implicated in protein-binding that can promote cell-matrix and/or cell-cell interactions (14) . However, no ligand or co-receptor has been identified for 5T4 to date. During embryonic development, 5T4 appears to regulate CXCR4-mediated chemotaxis (15) and modulates dendritic branching of granule cells in the developing olfactory bulb (16) .
The extracellular domain is critical for 5T4-mediated inhibition of Wnt/β-catenin signaling (17) . 5T4 has a short cytoplasmic domain consisting of 44 amino acids and aside from a serine-asparagine-valine motif that is implicated in binding PDZ-containing molecules, there are no classical signal transduction motifs contained in the sequence (14, 18) .
Studies with overexpression or knockdown of 5T4 have demonstrated that it likely plays a role in adhesion, cytoskeletal organization and motility, and epithelial-to-mesenchymal transition associated with metastasis (18) (19) (20) . 5T4 knockout mice are viable, though adults have a number of structural defects in the brain as a result of changes that occur during brain development in utero likely caused by the role of 5T4 in dendritic branching (15) . 5T4 is also expressed on cancer stem cells (CSCs) which are hypothesized to be responsible for chemotherapeutic resistance and recurrence of cancer (21, 22 cell populations (22) (23) (24) (25) (26) (27) (28) . Given the differences in mechanisms of action between these two payloads we wanted to compare the activities of these two drugs side-by-side.
We report data from in vitro and in vivo preclinical tumor models comparing the activity of the site-specifically conjugated ADCs 5T4-PBD and 5T4-Tub. The 5T4-PBD, subsequently labeled as MEDI0641, elicited superior anti-tumor activity than 5T4-Tub and reduced the CSC population in vivo unlike ADCs conjugated with either tubulysin or auristatin payloads. Following these observations, the preclinical safety and pharmacokinetic profile of MEDI0641 was evaluated in rats to assess its in vivo stability and off-target toxicity profile.
Materials & Methods

Generation of the lead anti-5T4 antibody, 5T4_0108
The parental antibody, A07, was derived by immunization of VelocImmune II mice (Regeneron, 29) with recombinant human 5T4 using a 48-day rest/boost immunization protocol (30) and was identified from a biochemical assay of hybridoma supernatants for binding to 5T4. This antibody underwent affinity optimization by CDR-directed mutagenesis (31) and phage display selection (32, 33) . The lead antibody, 5T4_0108, was identified in a biochemical assay where it demonstrated improved binding to 5T4 over the parental A07. This antibody was then expressed and purified as a full length, human IgG1 antibody containing the mutations L234F to significantly reduce FcγR binding, and S239C to provide engineered cysteines for site-specific conjugation of payloads, in the CH2 domain (34) based on EU numbering (35) .
Site-specific conjugation of warheads
Site-specific conjugates were generated as previously described (34) were derived from these working cell banks and were used within ten passages following thaw. After ten passages (typically within 2-3 months following thaw), cells were discarded and new cell vials were thawed as needed. All cell lines were cultured using ATCC-recommended media at 37°C in a humidified incubator with 5% CO 2 except for the MDA-MB-361 breast carcinoma cells that were cultured in atmospheric air at 37°C.
In vitro cytotoxicity
The cells were plated in culture media at a density of 2,000 to 5,000 per well (depending on the growth kinetics of each cell line) of tissue culture-treated 96-well plates in a volume of 80 μL and allowed to adhere overnight. A 5X stock of each concentration of antibody or ADC to be tested was prepared by diluting the test articles in culture medium. Twenty μL of each test article was added to cells in duplicate or triplicate such that the final dose curve ranged from 4 μg/mL down to 61 pg/mL in a stepwise 1:4 serial dilution series. The treated cells were cultured at 37°C / 5% CO 2 for 72 to 144 hours (depending on the growth kinetics of each particular cell line). The CellTiter-Glo ® (CTG) Luminescent Viability Assay (Promega) was used to determine relative cytotoxicity.
Briefly, 100 μL of CTG reagent was added to each well, allowed to incubate for 10 minutes at room temperature with mild shaking and then the absorbance of each sample at 560nM was read using an EnVision luminometer (Perkin Elmer). The percent cell viability was calculated by the following formula: (average luminescence of treated samples/average luminescence of control samples) x 100. IC 50 values were determined using logistic non-linear regression analysis with GraphPad Prism software.
In vivo efficacy studies
All in vivo studies were carried out in compliance with the guidelines published by the 
Evaluating effects on CSCs in tumors
Mice bearing NCI-N87 and MDA-MB-361 xenografts were treated with the indicated ADC and upon initial signs of tumor regression, tumors were excised, cut into 4 mm pieces and cryopreserved using Cryostor. Frozen tumor pieces were thawed at 37°C, A gross necropsy was performed on all main study animals and a standard list of organs, including brain, lung, liver, kidney, spleen, thymus, testes, heart, and bone, were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically by a board certified veterinary pathologist.
Additional Materials and Methods can be found in the Supplementary Data.
Results
Expression of 5T4 in clinical tumor samples
Previous reports have indicated that 5T4 is overexpressed in a variety of human carcinomas (6) (7) (8) (9) (10) (11) (12) (13) . To confirm these findings and to focus on cancer types with the highest incidence of 5T4 expression, extensive IHC of tumor microarrays and tumor samples as well as normal tissue arrays was conducted. 5T4 was broadly expressed in tumor microarrays and clinical tumor samples representing a number of cancer types, with the highest incidence in gastric cancer, non-small cell lung cancer (NSCLC), and HNSCC ( Fig. 1A) . At least 90% of tumors analyzed in each of these cancers had detectable levels of 5T4 expression by IHC, and in NSCLC samples, the prevalence of 5T4 was slightly higher in squamous NSCLC compared to adenocarcinoma. Greater than 60% of breast cancer specimens, including triple-negative samples, were 5T4-positive. Clear membrane localization of 5T4 immunostaining was prevalent in various types of cancers (Fig. 1B) . Although gastric cancers had the highest incidence of staining, only about 20% of samples could be classified as high/positive with a pathology score of 2+ or 3+ observed in greater than 50% of the tumor cells. In contrast, roughly 70% of all NSCLC and HNSCC samples exhibited high/positive staining.
Similar to previous findings (6,9), 5T4 expression in normal tissues was extremely limited with minimal expression observed in epithelial cells of the renal tubules, gastric glands, skin, adrenal gland, urinary bladder, gall bladder, uterus, and cervix.
Collectively, these data confirmed 5T4 would be a good tumor-associated antigen for a targeted approach such as an ADC, and identified potential indications to target in the clinic due to prevalent expression of 5T4.
Generation and in vitro characterization of 5T4_0108 antibody
A 5T4-specific antibody, A07, was isolated from transgenic mice expressing human antibody variable genes immunized with recombinant human 5T4. The K D of this antibody was measured to be approximately 100 nM as determined via Biacore analysis, therefore in vitro affinity optimization using phage display was conducted and led to the generation of 5T4_0108. 5T4_0108 is a human IgG1 with the following mutations engineered into the heavy chain CH2 domain based on EU numbering (35) Fig. S1 ).
The improved affinity translated into superior efficacy. 5T4-Tub which consists of 5T4_0108 conjugated with a tubulysin payload x, was 14-fold more potent than an ADC consisting of a site-specific variant of the parental antibody (ssA07) conjugated with the same payload (ssA07-Tub) ( Supplementary Fig. S2, Supplementary Table S1 ). As described above, the initial studies to evaluate a candidate anti-5T4 ADC were conducted with 5T4-Tub. However, the activity of cytotoxics can be context dependent, where certain classes of drugs are more effective than others depending on the type of cancer. Therefore studies were conducted to determine the relative activity of 5T4-Tub and 5T4-PBD, an ADC composed of 5T4_0108 conjugated with SG3249, a DNA crosslinking PBD payload (27) .
Comprehensive in vitro cytotoxicity assays were then conducted as an initial screen to compare relative activities of 5T4-PBD and 5T4-Tub. To determine if 5T4 expression levels impact ADC activity, these ADCs were tested against MDA-MB-361 breast cancer cells representing high 5T4 expression (~65,000 5T4 molecules/cell), DU 145 prostate cancer cells representing moderate 5T4 expression (~30,000 5T4 molecules/cell) and NCI-N87 gastric carcinoma cells representing low 5T4 expression levels (~4,000 5T4 molecules per cell) (Supplementary Table S2 ).
While the relative activities of 5T4-PBD and 5T4-Tub were comparable in each cell line, there was a clear correlation between the level of 5T4 expression and in vitro potency for both 5T4-ADCs in general (Fig. 2) . 5T4-PBD and 5T4-Tub were most potent against 5T4-high MDA-MB-361 cells generating IC 50 values in the pg/mL range based on antibody concentration (Table 1 ). In addition a greater maximum cytotoxicity was achieved at doses that are logs lower than what was needed in the other two cell lines. 
Both the PBD and tubulysin warheads should elicit apoptosis, and this was confirmed using companion in vitro assays. In one assay the % viability was assessed and in a second assay cleaved-caspase activity was used as an indicator of apoptosis (36) .
Following treatment with 5T4-PBD or 5T4-Tub (Supplementary Fig. S3 ), decreased viability is directly correlated with increased caspase 3/7 activity in various cell lines, confirming that both 5T4-PBD and 5T4-Tub induce an apoptotic cell death pathway.
In vivo anti-tumor activity of 5T4-PBD and 5T4-Tub
Collectively, the in vitro data suggest that both 5T4-PBD and 5T4-Tub were able to induce potent cytotoxicity via apoptosis in a target-dependent manner. To confirm that the in vitro activity of 5T4-PBD and 5T4-Tub could translate to potent anti-tumor activity in vivo, these ADCs were tested against tumors with varying levels of 5T4 expression as determined by IHC: NCI-N87 xenografts with low/moderate in vivo 5T4 expression, DU 145 xenografts with moderate levels of 5T4 expression and MDA-MB-361 xenografts with high 5T4 levels.
In the NCI-N87 model with low/moderate 5T4 levels, 5T4-PBD was able to achieve durable regression with a single administration of a 1 mg/kg dose, whereas 5T4-Tub achieved a period of regression with a 5 mg/kg dose administered QWx4, but then the tumors began to regrow shortly after cessation of treatment (Fig. 3A) . Initially, tumor regression was observed in the DU 145 model following QWx5 administration of either a 1 mg/kg dose of 5T4-PBD or a 5 mg/kg dose of 5T4-Tub (Fig. 3B) . However, the 5T4- In the MDA-MB-361 xenograft model expressing high levels of 5T4, both 5T4-Tub and 5T4-PBD achieved durable regressions, though a lower dose and less frequent dosing of 5T4-PBD was required to achieve such anti-tumor activity (Fig. 3C ). Statistical significance (P < 0.05 based on two-way ANOVA) was demonstrated for the 5T4-ADCs compared to controls. It should also be noted that no overt signs of toxicity such as significant body weight loss were observed with either ADC at the doses administered in these studies.
Anti-CSC activity of 5T4-PBD
To determine if the enhanced in vivo efficacy with the PBD-conjugated 5T4-PBD compared to the tubulysin-conjugated 5T4-Tub could be due to differential effects of their warheads on the CSC populations, studies were carried out to determine 5T4 (42) . In all cases, 5T4 expression on the CSC population was equal to or higher than that on nonCSCs (Fig. 4A) , even when the cell line had little to no 5T4 expression as a whole (Supplementary Fig. S4 ). We first determined the effects of the various warheads on CSCs in vitro. CSCenriched spheroids derived from several of these cell lines were treated with PBD, tubulysin or auristatin warheads to determine if these warheads could inhibit the growth of CSCs in vitro. The auristatin MMAE was included since an auristatin-conjugated 5T4-ADC has been reported to have activity against CSCs (23) . In our studies only the PBD dimer warhead potently inhibited CSC sphere formation in all lines tested with an IC 50 range of 0.18 -0.78 nM whereas the tubulysin or auristatin warheads had little to no effect ( Supplementary Fig. S5 ). This data suggest that the DNA cross-linking PBD dimer warhead could potently and specifically inhibit CSC proliferation whereas tubulin inhibitors may not. number of CSCs by approximately 50% in both models and was more effective than either the tubulysin-conjugated 5T4-Tub or the auristatin-conjugated 5T4-mcMMAF (Fig.   4B ).
The data suggest that the superior anti-tumor activity of 5T4-PBD could be due to the ability of this ADC to target 5T4 + CSCs in addition to the 5T4 + bulk tumor cells, whereas ADCs with tubulin inhibitors, such as 5T4-Tub, are ineffective at inhibiting CSCs. Since 5T4 is a target that is expressed on both CSCs as well as the non-CSCs within a tumor, it is critical to develop a 5T4-ADC conjugated with a payload capable of effectively targeting CSCs to produce the most durable response.
Tolerability of MEDI0641 in rats
Given the greater in vivo activity and anti-CSC activity observed with 5T4-PBD, this ADC was selected for further development and was designated as MEDI0641. The safety profile of the ADC was subsequently evaluated in a non-GLP rat toxicology study.
Although the 5T4 antibody does not cross-react with rodent 5T4, the rat was chosen as the initial toxicity species to evaluate the off-target toxicity profile and assess the in vivo stability of the molecule. Male rats were administered a single IV dose of 1 or 2 mg/kg of MEDI0641 on day 1 and necropsied on days 8 and 29 to evaluate acute and delayed toxicities. All animals survived until scheduled necropsy. Major findings were dosedependent decrease in body weight gain (up to 10%) and dose-dependent bone marrow suppression, with major effects on reticulocytes, platelets, and white blood cells (Fig. 5) . 
Discussion
MEDI0641 is a 5T4-targeting ADC conjugated with a PBD payload that is capable of inducing significant anti-tumor activity, including durable regressions in tumor models with varying intensity and heterogeneity of 5T4 expression. Though 5T4-Tub also demonstrated significant in vivo anti-tumor activity, MEDI0641 produced a more durable response possibly due to the fact that it had a more pronounced effect on CSCs than 5T4-Tub. We and others have shown that 5T4 is expressed on CSCs which are hypothesized to be responsible for chemotherapeutic resistance and recurrence of cancer (21, 22) . Using multiple HNSCC patient-derived xenograft (PDX) models, Kerk et al. reports that MEDI0641 was able to reduce, and in one model ablate, CSCs in these models, corroborating and extending the anti-CSC properties of MEDI0641 that we describe here. Like us, they also observed that 5T4 expression was increased in the 
lesions that are not easily repaired could more effectively target CSCs. The data presented here support this hypothesis. 5T4-mcMMAF conjugated with an auristatin payload had no effect on CSC populations in vivo in either xenograft model and 5T4-Tub was either ineffective or less effective against CSCs compared to MEDI0641 in the MDA-MB-361 and NCI-N87 xenograft models, respectively. Previously, an anti-5T4 ADC conjugated with the auristatin payload mcMMAF (A1-mcMMAF; PF-06263507) was reported to have potent anti-tumor activity in vivo and also was reported to inhibit CSC-like tumor-initiating cells in a NSCLC PDX model (23) . There could be several explanations for the conflicting data with the MMAF-conjugated ADCs: 1) The 5T4-mcMMAF ADC used in the present study was a site-specific conjugate with a DAR of 2, as opposed to the classically-conjugated A1-mcMMAF that has a DAR of ~4, 2) Prior to developing A1-mcMMAF, the same research group had evaluated a calicheamicin-conjugated 5T4-ADC, however composed of a different antibody against 5T4. They found that the ADC bearing the calicheamicin payload was not tolerated at efficacious exposure levels in cynomolgus monkeys (23, 50) . Though also a DNAtargeting agent, the mechanism of action of calicheamicin is different from that of PBDs, and the drivers of the toxicity with the 5T4-calicheamicin were not reported so it's not clear if they could be attributed to the different antibody and/or the different payload.
Non-GLP rat toxicology studies with MEDI0641 demonstrated a reasonable safety profile. Regardless, close attention to the toxicological findings with MEDI0641, particularly in a species where our anti-5T4 antibody cross-reacts is warranted as safety studies with this ADC proceed.
In conclusion, our generation and testing of the PBD-conjugated MEDI0641 and 5T4-Tub permitted a direct comparison of payloads with different mechanisms of action conjugated to the same antibody against 5T4. Our results demonstrated MEDI0641 had overall superior activity and in particular, is more effective at targeting 5T4-positive CSCs which may prevent or reduce tumor recurrence. These data provide motivation for further development of this promising ADC. were also included to determine target-specific binding. normalized to 100% and the data for other treatment groups are reported as a percent of the CSC population found in control tumors. 5T4-PBD decreased the CSC population by approximately 50% in both models. 5T4-Tub had no effect on the MDA-MB-361 CSCs but had some effect on NCI-N87 CSCs though this effect was not as potent as that with 5T4-PBD. Neither 5T4-mcMMAF nor controls had any effect on CSCs in either model. The 5T4-PBD-mediated decrease in CSCs was statistically significant compared to all groups in both models except the 5T4-Tub-treated group in the NCI-N87 model (P values < 0.05 based on unpaired T tests). 
